Bigfoot’s goal is to make pump-sensor therapy simpler than the pump companies before them have. They envision themselves as a service provider rather than a hardware or device company. Their service will be to “do a better job delivering insulin,” automating your between-meal insulin therapy, the communication between your pump and your Dexcom CGM, even so far as serving as a single point of contact for all of your supply and prescription inventory management, sending you supplies when you need them, “connecting everything, making it intuitive,” says Brewer. Read more
While we will not see a true artificial pancreas – a closed-loop insulin pump and continuous glucose monitoring system – come to market in 2016, we are so close we can artificially taste it. Read more
Medtronic, Inc. announced the global launch of the MiniMed 640G System, the next breakthrough toward an artificial pancreas.
The system is the first in the world to both automatically suspend insulin delivery when sensor glucose levels are predicted to approach a low limit, and then resume insulin delivery once sensor glucose levels recover. Read more
In June of 2013 I had the opportunity to hear Tom Brobson speak about his participation in the University of Virginia’s Artificial Pancreas Project. I was familiar with the AP project progress over the years and had gone to other … Read more
Prescript: It’s been a while since I’ve written, I know. I had a beautiful baby boy who is now nearly six months old. Perfect and perfectly healthy, so take that, diabetes! This post is about other things, though. Four years … Read more
JDRF has announced a two partnerships to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).
Five adults in the UK with type 1 diabetes have used an artificial pancreas in their homes without medical supervision. This step offers real hope for a future where people with type 1 diabetes no longer have to monitor blood glucose levels, and where they have a better chance of living a long and healthy life. Read more
JDRF and Tandem Diabetes Care, the company behind the t:slim insulin pump, have teamed up to develop a dual-chamber infusion pump for the management of diabetes. The partnership agreement is designed to accelerate the development of a next-generation, fully automated artificial pancreas system. Read more
The Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel Inc. a grant for the development of novel and stable glucagon formulations for use in an artificial pancreas, also known as a closed loop pump system.
The SBIR program is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development that has the potential for commercialization. Read more
Positive results from the first feasibility study of an advanced first-generation artificial pancreas system were presented at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System… Read more